Tarek Hassanein

20.2k total citations · 4 hit papers
211 papers, 8.3k citations indexed

About

Tarek Hassanein is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Tarek Hassanein has authored 211 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 167 papers in Hepatology, 128 papers in Epidemiology and 40 papers in Surgery. Recurrent topics in Tarek Hassanein's work include Liver Disease Diagnosis and Treatment (111 papers), Hepatitis C virus research (98 papers) and Liver Disease and Transplantation (68 papers). Tarek Hassanein is often cited by papers focused on Liver Disease Diagnosis and Treatment (111 papers), Hepatitis C virus research (98 papers) and Liver Disease and Transplantation (68 papers). Tarek Hassanein collaborates with scholars based in United States, France and United Kingdom. Tarek Hassanein's co-authors include William Perry, Robin C. Hilsabeck, Jared W. Allen, Sangeeta N. Bhatia, Claude B. Sirlin, Jan Stange, Edward Tam, Mark Sulkowski, Ravindra L. Mehta and David H. Van Thiel and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Tarek Hassanein

203 papers receiving 8.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

2015 477 citations David R. Nelson, Paul Martin et al. profile →
Diagnostic Performance of Magnetic Resonance Elastography in Staging Liver Fibrosis: A Systematic Review and Meta-analysis of Individual Participant Data

2014 414 citations Tarek Hassanein, Andrew P. Keaveny et al. Clinical Gastroenterology and Hepatology profile →
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

2014 395 citations Ira M. Jacobson, Fred Poordad et al. profile →
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

2022 157 citations Naim Alkhouri, Robert Herring et al. Journal of Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tarek Hassanein United States	46	5.9k	5.4k	1.5k	827	525	211	8.3k
Jorge Rakela United States	55	6.3k 1.1×	6.0k 1.1×	2.7k 1.9×	522 0.6×	516 1.0×	205	10.1k
Paul Y. Kwo United States	53	6.6k 1.1×	5.5k 1.0×	2.0k 1.4×	1.2k 1.4×	411 0.8×	253	9.5k
Thomas D. Schiano United States	47	5.2k 0.9×	4.3k 0.8×	3.6k 2.5×	416 0.5×	509 1.0×	380	9.2k
John O’Grady United Kingdom	45	4.2k 0.7×	3.5k 0.6×	2.6k 1.8×	334 0.4×	876 1.7×	200	8.2k
Gregory T. Everson United States	63	10.1k 1.7×	8.6k 1.6×	3.8k 2.6×	1.0k 1.3×	1.1k 2.1×	264	14.4k
Yves Horsmans Belgium	48	4.7k 0.8×	5.3k 1.0×	1.3k 0.9×	666 0.8×	1.1k 2.1×	238	9.5k
Ricard Solà Spain	31	7.8k 1.3×	6.7k 1.3×	1.8k 1.3×	397 0.5×	417 0.8×	75	9.8k
Paul Calès France	55	7.7k 1.3×	9.0k 1.7×	2.4k 1.7×	366 0.4×	1.1k 2.1×	305	11.5k
Yogesh Chawla India	48	5.7k 1.0×	5.4k 1.0×	2.8k 1.9×	522 0.6×	763 1.5×	277	8.5k
Dominique Thabut France	50	6.2k 1.1×	6.6k 1.2×	2.0k 1.4×	283 0.3×	484 0.9×	207	8.5k

Countries citing papers authored by Tarek Hassanein

Since Specialization

Citations

This map shows the geographic impact of Tarek Hassanein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tarek Hassanein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tarek Hassanein more than expected).

Fields of papers citing papers by Tarek Hassanein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tarek Hassanein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tarek Hassanein. The network helps show where Tarek Hassanein may publish in the future.

Co-authorship network of co-authors of Tarek Hassanein

This figure shows the co-authorship network connecting the top 25 collaborators of Tarek Hassanein. A scholar is included among the top collaborators of Tarek Hassanein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tarek Hassanein. Tarek Hassanein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stange, Jan, Nikolaos Pyrsopoulos, Tarek Hassanein, et al.. (2025). Bacterial Infections in Patients With Severe Alcohol‐Associated Hepatitis: Drivers of Organ Failure and Mortality. Liver International. 45(6). e70111–e70111.

Lobo, Julio, Caitlin Schneider, Samuel Klein, et al.. (2024). Methods and validation of velacur determined fat fraction in patients with MASLD. SHILAP Revista de lepidopterología. 2(2). 100061–100061. 1 indexed citations

Hassanein, Tarek, Andrew P. Keaveny, Parvez Mantry, et al.. (2024). Liver function and portal‐systemic shunting quantified by the oral cholate challenge test and risk for large oesophageal varices. Alimentary Pharmacology & Therapeutics. 60(2). 246–256. 10 indexed citations

Alkhouri, Naim, Robert Herring, Heidi Kabler, et al.. (2022). Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. Journal of Hepatology. 77(3). 607–618. 157 indexed citations breakdown →

Agarwal, Kosh, Jia Xu, Edward Gane, et al.. (2022). Safety, pharmacokinetics and antiviral activity of ABI‐H2158, a hepatitis B virus core inhibitor: A randomized, placebo‐controlled phase 1 study. Journal of Viral Hepatitis. 30(3). 209–222. 4 indexed citations

Lawitz, Eric, Fred Poordad, Leah J. Anderson, et al.. (2019). Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection. Journal of Viral Hepatitis. 26(6). 675–684. 5 indexed citations

Soliman, Gamal A., et al.. (2019). Mass screening for hepatitis B and C in Southern Upper Egypt. BMC Public Health. 19(1). 1326–1326. 12 indexed citations

Terrault, Norah A., Francesco Bibbiani, Yi‐Cheng Chen, et al.. (2017). Superiority of Avatrombopag (AVA) to Placebo (PBO) for the Treatment of Chronic Liver Disease (CLD)-Associated Thrombocytopenia (TCP) in Patients Undergoing Scheduled Procedures: Results of 2 Randomized, PBO-Controlled Phase 3 Studies. Hepatology. 2 indexed citations

Foster, Graham R., Carmine Coppola, Moutaz Derbala, et al.. (2016). Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. PLoS ONE. 11(3). e0151703–e0151703. 15 indexed citations

10.

Gane, Edward, Fred Poordad, Stanley Wang, et al.. (2016). High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology. 151(4). 651–659.e1. 72 indexed citations

11.

Terrault, Norah A. & Tarek Hassanein. (2016). Management of the patient with SVR. Journal of Hepatology. 65(1). S120–S129. 45 indexed citations

12.

Morgan, Timothy R., Kathryn Osann, Teodoro Bottiglieri, et al.. (2015). A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP. Cancer Prevention Research. 8(9). 864–872. 15 indexed citations

13.

Flamm, Steven L., Edward Gane, Jean‐François Dufour, et al.. (2014). Safety of ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients >= 65 Years of Age: Results From Phase 2 and 3 Trials. Hepatology. 60. 4 indexed citations

14.

Nelson, David R., K. Rajender Reddy, Adrian M. Di Bisceglie, et al.. (2014). ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients with History of Depression or Bipolar Disorder: Pooled Analysis of Efficacy and Safety in Phase 3 Trials. Hepatology. 60. 5 indexed citations

15.

Hézode, Christophe, Laurent Alric, Ashley Brown, et al.. (2014). 819Daclatasvir in Combination with Peginterferon Alfa-2a and Ribavirin for Treatment-Naive Patients with HCV Genotype 4 Infection: Phase 3 COMMAND-4 Results. Open Forum Infectious Diseases. 1(suppl_1). S233–S233. 5 indexed citations

16.

Nelson, David R., Gary L. Davis, Ira M. Jacobson, et al.. (2008). Hepatitis C Virus: A Critical Appraisal of Approaches to Therapy. Clinical Gastroenterology and Hepatology. 7(4). 397–414. 11 indexed citations

17.

Perry, William, Robin C. Hilsabeck, & Tarek Hassanein. (2007). Cognitive Dysfunction in Chronic Hepatitis C: A Review. Digestive Diseases and Sciences. 53(2). 307–321. 103 indexed citations

18.

Sullivan, Sean D., Donald M. Jensen, David Bernstein, et al.. (2004). Cost-Effectiveness of Combination Peginterferon alpha-2a and Ribavirin Compared With Interferon alpha-2b and Ribavirin in Patients With Chronic Hepatitis C. The American Journal of Gastroenterology. 99(8). 1490–1496. 47 indexed citations

19.

Bisceglie, Adrian M. Di, André Castro Lyra, Myron Schwartz, et al.. (2003). Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. The American Journal of Gastroenterology. 98(9). 2060–2063. 149 indexed citations

20.

Gürakar, Ahmet, S. Fagiuoli, Tarek Hassanein, et al.. (1994). Prophylactic alpha-interferon therapy following liver transplantation: does it prevent allograft infection?. European Journal of Gastroenterology & Hepatology. 6(5). 429–432. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact